Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Aug 10:14:1142276.
doi: 10.3389/fendo.2023.1142276. eCollection 2023.

Regulation of autophagy by natural polyphenols in the treatment of diabetic kidney disease: therapeutic potential and mechanism

Affiliations
Review

Regulation of autophagy by natural polyphenols in the treatment of diabetic kidney disease: therapeutic potential and mechanism

Tongtong Liu et al. Front Endocrinol (Lausanne). .

Abstract

Diabetic kidney disease (DKD) is a major microvascular complication of diabetes and a leading cause of end-stage renal disease worldwide. Autophagy plays an important role in maintaining cellular homeostasis in renal physiology. In DKD, the accumulation of advanced glycation end products induces decreased renal autophagy-related protein expression and transcription factor EB (TFEB) nuclear transfer, leading to impaired autophagy and lysosomal function and blockage of autophagic flux. This accelerates renal resident cell injury and apoptosis, mediates macrophage infiltration and phenotypic changes, ultimately leading to aggravated proteinuria and fibrosis in DKD. Natural polyphenols show promise in treating DKD by regulating autophagy and promoting nuclear transfer of TFEB and lysosomal repair. This review summarizes the characteristics of autophagy in DKD, and the potential application and mechanisms of some known natural polyphenols as autophagy regulators in DKD, with the goal of contributing to a deeper understanding of natural polyphenol mechanisms in the treatment of DKD and promoting the development of their applications. Finally, we point out the limitations of polyphenols in current DKD research and provide an outlook for their future research.

Keywords: autophagy; diabetic kidney disease; lysosome; natural polyphenols; transcription factor EB.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Characteristics of autophagy in DKD. (The mTOR, AMPK, and SIRT1-regulated autophagy pathway is an important protective mechanism for DKD. Mitophagy and lipophagy are critical to DKD. There is a close crosstalk between autophagy and inflammation. Lysosomes promote the degradation of AGEs).
Figure 2
Figure 2
Autophagy as a therapeutic target in DKD. (Autophagy is inhibited in DKD. Autophagy-lysosome dysfunction mediates podocyte injury leading to glomerulosclerosis and massive proteinuria and mediates renal proximal tubular epithelial cells injury aggravating renal fibrosis, and mediates mesangial cell injury and endothelial-to-mesenchymal transition promoting the production of mesangial matrix and aggravating glomerulosclerosis and proteinuria. In addition, inhibition of macrophage autophagy aggravated renal inflammation leading to glomerulosclerosis, proteinuria, and renal fibrosis).
Figure 3
Figure 3
Polyphenols are used to regulate autophagy in DKD. (Natural polyphenols are potential autophagy regulators. Polyphenols are mainly through the SIRT1 pathway, mTOR pathway, and AMPK pathway is involved in the regulation of various links of autophagy. In addition, polyphenols can also improve the autophagy-lysosome pathway by activating TFEB and promoting its nuclear translocation. In conclusion, polyphenols play an important role in improving DKD by regulating autophagy-lysosome pathway to improve renal inflammation, lipid metabolism, mitochondrial homeostasis, apoptosis, and fibrosis.

Similar articles

Cited by

References

    1. Rayego-Mateos S, Rodrigues-Diez R, Fernandez-Fernandez B, Mora-Fernández C, Marchant V, Donate-Correa J, et al. . Targeting inflammation to treat diabetic kidney disease: the road to 2030. Kidney Int (2022) 103(2):282–96. doi: 10.1016/j.kint.2022.10.030 - DOI - PubMed
    1. Forst T, Mathieu C, Giorgino F, Wheeler DC, Papanas N, Schmieder RE, et al. . New strategies to improve clinical outcomes for diabetic kidney disease. BMC Med (2022) 20(1):337. doi: 10.1186/s12916-022-02539-2 - DOI - PMC - PubMed
    1. Chan JCN, Lim LL, Wareham NJ, Shaw JE, Orchard TJ, Zhang P, et al. . The lancet commission on diabetes: using data to transform diabetes care and patient lives. Lancet (London England) (2021) 396(10267):2019–82. doi: 10.1016/s0140-6736(20)32374-6 - DOI - PubMed
    1. Brosius FC, Cherney D, Gee PO, Harris RC, Kliger AS, Tuttle KR, et al. . Transforming the care of patients with diabetic kidney disease. Clin J Am Soc Nephrology (2021) 16(10):1590–600. doi: 10.2215/cjn.18641120 - DOI - PMC - PubMed
    1. Ricciardi CA, Gnudi L. Kidney disease in diabetes: From mechanisms to clinical presentation and treatment strategies. Metabolism: Clin Experimental (2021) 124:154890. doi: 10.1016/j.metabol.2021.154890 - DOI - PubMed

Publication types